| scholarly article | Q13442814 |
| review article | Q7318358 |
| P356 | DOI | 10.1016/J.EXPNEUROL.2009.09.011 |
| P8608 | Fatcat ID | release_hb5vv57ij5bblpj67b4c2hapgi |
| P698 | PubMed publication ID | 19782073 |
| P50 | author | José J. Lucas | Q42463527 |
| Felix Hernandez | Q56506261 | ||
| Almudena Fuster-Matanzo | Q114717313 | ||
| Elena Gómez de Barreda | Q114717314 | ||
| Jesús Ávila de Grado | Q5930854 | ||
| P433 | issue | 2 | |
| P407 | language of work or name | English | Q1860 |
| P304 | page(s) | 322-325 | |
| P577 | publication date | 2009-09-24 | |
| P1433 | published in | Experimental Neurology | Q5421127 |
| P1476 | title | GSK3: a possible link between beta amyloid peptide and tau protein | |
| P478 | volume | 223 |
| Q86986333 | A combination extract of Renshen (Panax Ginseng), Yinyanghuo (Herba Epimedii Brevicornus), Yuanzhi (Radix Palygalae) and Jianghuang (Rhizoma Curcumae Longae) decreases glycogen synthase kinase 3beta expression in brain cortex of APPV7171 transgenic |
| Q42147254 | A unifying hypothesis for familial and sporadic Alzheimer's disease |
| Q48518436 | Abcg2 deficiency augments oxidative stress and cognitive deficits in Tg-SwDI transgenic mice. |
| Q38443497 | Activation of mTOR: a culprit of Alzheimer's disease? |
| Q87056766 | Amyloid beta-derived diffusible ligands (ADDLs) induce abnormal expression of insulin receptors in rat hippocampal neurons |
| Q30414554 | Amyloid-β signals through tau to drive ectopic neuronal cell cycle re-entry in Alzheimer's disease. |
| Q35971305 | Angiotensin II, a Neuropeptide at the Frontier between Endocrinology and Neuroscience: Is There a Link between the Angiotensin II Type 2 Receptor and Alzheimer's Disease? |
| Q48901829 | Atorvastatin ameliorates cognitive impairment, Aβ1-42 production and Tau hyperphosphorylation in APP/PS1 transgenic mice |
| Q38121045 | Axin: an emerging key scaffold at the synapse |
| Q38020618 | Axonal degeneration in Alzheimer's disease: when signaling abnormalities meet the axonal transport system. |
| Q27022080 | Axonal transport of APP and the spatial regulation of APP cleavage and function in neuronal cells |
| Q35496991 | Behavioral deficit, oxidative stress, and mitochondrial dysfunction precede tau pathology in P301S transgenic mice |
| Q38592451 | Behind the curtain of tauopathy: a show of multiple players orchestrating tau toxicity |
| Q56990860 | Biology-oriented development of novel lipophilic antioxidants with neuroprotective activity |
| Q42323226 | Cannabidiol Modulates the Expression of Alzheimer's Disease-Related Genes in Mesenchymal Stem Cells |
| Q90403925 | Cerebrospinal fluid phospho-tau T217 outperforms T181 as a biomarker for the differential diagnosis of Alzheimer's disease and PET amyloid-positive patient identification |
| Q47981799 | Chronic Lithium Treatment in a Rat Model of Basal Forebrain Cholinergic Depletion: Effects on Memory Impairment and Neurodegeneration |
| Q47110701 | Cognitive Decline in Preclinical Alzheimer's Disease: Amyloid-Beta versus Tauopathy |
| Q88419158 | Combating Neurodegenerative Diseases with the Plant Alkaloid Berberine: Molecular Mechanisms and Therapeutic Potential |
| Q28302106 | DISC1-binding proteins in neural development, signalling and schizophrenia |
| Q48385313 | Decreased axonal transport rates in the Tg2576 APP transgenic mouse: improvement with the gamma-secretase inhibitor MRK-560 as detected by manganese-enhanced MRI. |
| Q43599319 | Decreased expression of Gab2 in patients with temporal lobe epilepsy and pilocarpine-induced rat model |
| Q36961488 | Dietary phytochemicals and cancer prevention: Nrf2 signaling, epigenetics, and cell death mechanisms in blocking cancer initiation and progression. |
| Q33700331 | Dysregulation of the mTOR pathway mediates impairment of synaptic plasticity in a mouse model of Alzheimer's disease |
| Q90396297 | Early active immunization with Aβ3-10-KLH vaccine reduces tau phosphorylation in the hippocampus and protects cognition of mice |
| Q46293996 | Effects of cannabidiol interactions with Wnt/β-catenin pathway and PPARγ on oxidative stress and neuroinflammation in Alzheimer's disease |
| Q27024232 | Emerging drug targets for Aβ and tau in Alzheimer's disease: a systematic review |
| Q54559951 | Enhanced catecholamine release in mice expressing PKB/SGK-resistant GSK3. |
| Q24610904 | Evidence for irreversible inhibition of glycogen synthase kinase-3β by tideglusib |
| Q42748129 | GSK3 Function in the Brain during Development, Neuronal Plasticity, and Neurodegeneration |
| Q89478137 | Glycogen synthase kinase-3 signaling in Alzheimer's disease |
| Q48172954 | Glycogen synthase kinase-3β (GSK3β) expression in a mouse model of Alzheimer's disease: a light and electron microscopy study |
| Q38069825 | How does angiotensin AT(2) receptor activation help neuronal differentiation and improve neuronal pathological situations? |
| Q33883285 | Hsc70 rapidly engages tau after microtubule destabilization |
| Q44285130 | Huprine X and huperzine A improve cognition and regulate some neurochemical processes related with Alzheimer's disease in triple transgenic mice (3xTg-AD). |
| Q34917354 | Hyperphosphorylated Tau in an α-synuclein-overexpressing transgenic model of Parkinson's disease |
| Q92255972 | Increased prefrontal cortex interleukin-2 protein levels and shift in the peripheral T cell population in progressive supranuclear palsy patients |
| Q36167749 | Induction of mitochondrial changes associated with oxidative stress on very long chain fatty acids (C22:0, C24:0, or C26:0)-treated human neuronal cells (SK-NB-E). |
| Q36708392 | Inhibition of Glycogen Synthase Kinase-3β (GSK-3β) as potent therapeutic strategy to ameliorates L-dopa-induced dyskinesia in 6-OHDA parkinsonian rats |
| Q47740742 | Insulin sensitizers improve learning and attenuate tau hyperphosphorylation and neuroinflammation in 3xTg-AD mice |
| Q35001864 | Insulin suppresses the expression of amyloid precursor protein, presenilins, and glycogen synthase kinase-3beta in peripheral blood mononuclear cells |
| Q37969262 | Interaction between pathogenic proteins in neurodegenerative disorders |
| Q53324250 | Interaction between α-synuclein and other proteins in neurodegenerative disorders. |
| Q48311391 | Kidins220 accumulates with tau in human Alzheimer's disease and related models: modulation of its calpain-processing by GSK3β/PP1 imbalance |
| Q58557345 | Kororamides, Convolutamines, and Indole Derivatives as Possible Tau and Dual-Specificity Kinase Inhibitors for Alzheimer's Disease: A Computational Study |
| Q28385932 | Lead exposure increases levels of β-amyloid in the brain and CSF and inhibits LRP1 expression in APP transgenic mice |
| Q39352421 | Lipidomic Profiles in Diabetes and Dementia. |
| Q35752353 | Mechanism of Oxidative Stress and Synapse Dysfunction in the Pathogenesis of Alzheimer's Disease: Understanding the Therapeutics Strategies |
| Q60046676 | Molecular Bases of Alzheimer’s Disease and Neurodegeneration: The Role of Neuroglia |
| Q34735544 | Molecular mechanisms of environmental enrichment: impairments in Akt/GSK3β, neurotrophin-3 and CREB signaling |
| Q39281484 | NUB1 modulation of GSK3β reduces tau aggregation |
| Q37029561 | Natural products as a source of Alzheimer's drug leads |
| Q38263124 | Natural products from marine organisms with neuroprotective activity in the experimental models of Alzheimer's disease, Parkinson's disease and ischemic brain stroke: their molecular targets and action mechanisms |
| Q56888282 | Neuronal calcineurin transcriptional targets parallel changes observed in Alzheimer disease brain |
| Q38012044 | Neuroprotective effect of natural products against Alzheimer's disease. |
| Q34563358 | Neuroprotective effects of treadmill exercise on BDNF and PI3-K/Akt signaling pathway in the cortex of transgenic mice model of Alzheimer's disease |
| Q38149943 | New insights into the role of glycogen synthase kinase-3 in Alzheimer's disease. |
| Q36595737 | Novel GαS-protein signaling associated with membrane-tethered amyloid precursor protein intracellular domain. |
| Q47104779 | Overexpression of Tau Rescues Nogo-66-Induced Neurite Outgrowth Inhibition In Vitro |
| Q35191233 | Paclitaxel-induced neuropathy: potential association of MAPT and GSK3B genotypes |
| Q26850298 | Pathogenic protein seeding in Alzheimer disease and other neurodegenerative disorders |
| Q42659976 | Potential neuroprotective strategies against tauopathy |
| Q48698344 | RNA Interference Silencing of Glycogen Synthase Kinase 3β Inhibites Tau Phosphorylation in Mice with Alzheimer Disease |
| Q36069777 | Reduction in inflammation and the expression of amyloid precursor protein and other proteins related to Alzheimer's disease following gastric bypass surgery |
| Q30630506 | Regulating prefrontal cortex activation: an emerging role for the 5-HT₂A serotonin receptor in the modulation of emotion-based actions? |
| Q38371329 | Regulation by glycogen synthase kinase-3 of inflammation and T cells in CNS diseases |
| Q39243689 | Regulation of motor proteins, axonal transport deficits and adult-onset neurodegenerative diseases |
| Q38188732 | Regulation of protein conformation by Pin1 offers novel disease mechanisms and therapeutic approaches in Alzheimer's disease |
| Q37294108 | Rescue of Early bace-1 and Global DNA Demethylation by S-Adenosylmethionine Reduces Amyloid Pathology and Improves Cognition in an Alzheimer's Model |
| Q38176898 | Role of wnt signaling in the control of adult hippocampal functioning in health and disease: therapeutic implications. |
| Q38139897 | SUMO: a (oxidative) stressed protein. |
| Q36644694 | Single-nucleotide polymorphisms of GSK3B, GAB2 and SORL1 in late-onset Alzheimer's disease: interactions with the APOE genotype |
| Q36128825 | Small-Molecule Inhibitors of GSK-3: Structural Insights and Their Application to Alzheimer's Disease Models |
| Q35972860 | Stabilization of Microtubule-Unbound Tau via Tau Phosphorylation at Ser262/356 by Par-1/MARK Contributes to Augmentation of AD-Related Phosphorylation and Aβ42-Induced Tau Toxicity |
| Q42180899 | Tau Phosphorylation by GSK3 in Different Conditions |
| Q52679169 | Tau Spreading Mechanisms; Implications for Dysfunctional Tauopathies. |
| Q36475393 | The Ever-Changing Morphology of Hippocampal Granule Neurons in Physiology and Pathology |
| Q33692255 | The Hsp70/Hsp90 Chaperone Machinery in Neurodegenerative Diseases |
| Q38793357 | The Neuroprotective Effects of Justicidin A on Amyloid Beta25-35-Induced Neuronal Cell Death Through Inhibition of Tau Hyperphosphorylation and Induction of Autophagy in SH-SY5Y Cells |
| Q92257585 | The Potential Role of MicroRNA-124 in Cerebral Ischemia Injury |
| Q34703974 | The fibroblast growth factor 14·voltage-gated sodium channel complex is a new target of glycogen synthase kinase 3 (GSK3). |
| Q55364582 | The impact of GAB2 genetic variations on cerebrospinal fluid markers in Alzheimer's disease. |
| Q54977801 | The novel histone de acetylase 6 inhibitor, MPT0G211, ameliorates tau phosphorylation and cognitive deficits in an Alzheimer's disease model. |
| Q35225615 | Thermodynamics of the interaction between Alzheimer's disease related tau protein and DNA |
| Q38234883 | Ubiquitin pathways in neurodegenerative disease |
| Q38101982 | Understanding the relationship between GSK-3 and Alzheimer's disease: a focus on how GSK-3 can modulate synaptic plasticity processes |
| Q27000787 | Wnt signaling in the vertebrate central nervous system: from axon guidance to synaptic function |
| Q48957652 | β-amyloid impairs the regulation of N-methyl-D-aspartate receptors by glycogen synthase kinase 3. |
Search more.